How does particle size affect performance of Tadalafil Powder?

Particle size is one of the invisible but very important factors of an active medicinal ingredient. Particle size of Tadalafil Powder may impact the rate of wetting, dispersion and dissolution during formulation which may enhance the performance of the completed dosage form. This is especially pertinent since tadalafil has extremely poor water solubility and is often described as a BCS Class II pharmacological ingredient in pharmaceutical research. In FDA review papers, tadalafil is described as being essentially insoluble in water. Published pharmaceutical research has recognized low solubility as a major barrier for formulation. Thus, for purchasers assessing API providers, particle size should be examined in conjunction with assay, contaminants, residual solvents, polymorphic form, moisture, and other quality parameters. In this context, Shaanxi Hongda Phytochemistry Co., Ltd. can be seen as a supplier whose manufacturing and quality-control approach needs to be evaluated not only by chemical purity but also by the consistency of physical characteristics relevant to downstream formulation.

Why does particle size deserve attention in Tadalafil Powder?

Low water solubility makes dissolution an important consideration

Tadalafil is an active pharmacological constituent with limited water solubility. During an FDA examination of a tadalafil product, the API was observed to be essentially insoluble in water and to have poor aqueous solubility over the physiological pH range studied. The applicant categorized tadalafil as a BCS Class II chemical; however, the FDA reviewer observed that a formal BCS classification was not sought in that application.

This is especially important when talking about particle size. A poorly soluble medication does not inevitably become more soluble by making the particles smaller. Rather, smaller particles often have a greater accessible surface area and may enhance the pace at which the solid interacts with the dissolving media. Dissolution is often a significant aspect of the total absorption process for BCS Class II chemicals, which is why particle engineering is often addressed during formulation development.

This means in practice that particle size should not be treated as a single criterion. It is one of the physical characteristics of the API that has to be examined together with crystal structure, surface properties, formulation composition, and the desired dosage form.

Surface area changes as particles become smaller

Smaller particles have a greater total surface area than bigger particles for the same quantity of material. This simple connection explains the enormous interest in micronization for poorly soluble medicinal molecules.

The increase in the surface area exposed to the dissolving media also enhances the chance of solvent molecules interacting with the drug particles. This may speed dissolving under proper formulation circumstances. Established ways to increase the dissolving performance of poorly soluble medicines include particle-size reduction, micronization, and nanosizing.

But smaller is not always the best. Very tiny particles might be cohesive, agglomerate, have poor flow, or react differently during blending and compression. So frequently the goal of particle engineering is not to get the smallest feasible particle size. A more relevant aim is to develop a particle-size distribution compatible with the desired formulation without causing additional production issues.

Particle size distribution can be more informative than one average value

D10, D50 and D90 provide a clearer picture

A remark like ‘the particle size is 20 microns’ does not provide the formulator what they need to know about an API. A powder may have particles scattered around that value, but the breadth and form of the distribution may be somewhat different from batch to batch.

The particle size distribution is often expressed in terms of percentiles such as D10, D50, and D90. D50 is the median particle size. D10 and D90 are indicative for the bottom and higher sections of the observed range. When these values are taken together, it offers a more meaningful picture of whether the material is reasonably thin or includes a considerable fraction of considerably finer or coarser particles.

This difference may become crucial during scale-up for Tadalafil Powder. Two batches might have comparable D50 values but respond differently if one has a bigger coarse proportion or a higher population of extremely tiny particles. A procurement specification that takes into account the dispersion and not just a notional average may consequently provide greater control over downstream processes.

Extremely broad distributions may create processing challenges

A wide particle-size distribution is not in itself a quality defect. In certain formulations a particular distribution may be purposefully chosen because it offers a good compromise between flow, packing, dissolution, and manufacturability.

The problem is when the distribution changes abruptly between batches. An increased percentage of tiny particles may cause increased cohesion and problematic feeding or mixing. Coarser particles may modify the dissolving behavior or the homogeneity of the final mix. The impacts are highly dependent on the formulation and processing circumstances, and hence the correct PSD should be determined via development work and not taken from a general industry objective.

This is also why the ability to duplicate the agreed physical profile might be more useful than merely advertising a very tiny particle size.

How particle size influences dissolution without changing intrinsic solubility？

Faster dissolution is not the same as higher solubility

Particle size reduction may enhance the dissolving rate by increasing surface area but does not necessarily modify the inherent equilibrium solubility of tadalafil. Solubility tells us how much of a material can dissolve under given circumstances, and dissolution rate tells us how fast that process happens.

Faster dissolution may be of use for a weakly water-soluble API, since the medication must get into solution before it can be accessible for absorption. But the size of the particles is not the only thing that impacts the result. The outcome may be influenced by the formulation vehicle, excipients, wetting behavior, solid-state characteristics, dissolving media, and gastrointestinal environment.

Hence, decrease of particle size is one of the formulation strategies for BCS Class II medications, not a general answer. Other solubility improvement procedures include solid dispersions, nanosuspensions, complexation, pH alteration, and others.

Tadalafil formulation research shows that other physical properties matter

Published literature on tadalafil has been reviewed for solid dispersions and alternative formulation strategies to enhance solubility. For example, research tested tadalafil solid dispersions with various polymers and determined their apparent solubility and dissolving properties.

This study underlines an essential aspect to API purchasers: that particle size cannot be dissociated from the overall physical and chemical properties of the material. When a provider modifies the milling or crystallization process, the material produced may alter not just in particle size but also in shape, surface qualities, or solid-state attributes. The effect of these adjustments should be assessed and not just assumed that a lower D50 translates to higher formulation performance.

Manufacturing method can determine the final particle profile

Crystallization establishes much of the starting morphology

Crystallization circumstances may affect the crystal size, shape, surface properties, and the distribution of particle sizes. The formation and growth of crystals may be influenced by the choice of solvent, the degree of supersaturation, the temperature profile, the mixing conditions, the use of seeding, and the period of crystallization.

This is especially important when a pharmaceutical producer needs a repeatable API. Additional effort in the downstream formulation may be created by a technique that delivers the necessary chemical purity but results in extremely variable crystal shape.

Thus, the chemical quality and physical quality of Tadalafil Powder should be considered simultaneously in process development. The objective is not only to generate tadalafil with the right molecular identity but also to produce material in a consistent manner that can be handled and formed to the customer’s specifications.

Milling can reduce size but requires process control

Mechanical milling is another way to change the size of particles. It may comminute bigger particles into a smaller-sized fraction, but excessive or poorly regulated milling might produce a broader fine-particle population or enhance particle cohesiveness.

The result relies on the equipment, milling intensity, feed qualities, residence duration, and the properties of the starting material. Thus, it is important to describe the powder after milling rather than judging the process setting.

A good strategy for manufacturing is to first specify the required particle-size profile and then determine process conditions that can reproduce it. This changes the question from “how fine can the powder be made?” to “what is the physical profile that the formulation actually needs?”

Particle size, morphology, and solid-state properties should be evaluated together

A particle is more than a diameter

Particle size measurements are useful; however, diameter alone does not capture the whole physical behavior of a medicinal powder.

Particle shape may influence flow, packing, surface contact, and powder handling. The behavior of irregular particles may vary from that of more uniform crystalline particles even when the size measured is comparable. Fine particles may also agglomerate. This means that the apparent size determined under one analytical condition may not reflect the behavior of the powder throughout processing.

Another aspect is solid-state characteristics. The medicinal efficacy might be affected by different crystal shapes or variations in crystallinity irrespective of the particle size. This is why a professionally structured API quality program does not consider PSD as a substitute for solid-state characterization.

So the most significant concern for buyers is not just whether the provider has “fine Tadalafil powder," but whether the supplier can maintain a repeatable physical profile and provide sufficient analytical data.

How particle-size testing supports batch consistency？

Laser diffraction is useful for distribution measurement

Laser diffraction is a commonly used technique for characterizing particle-size distributions, as it enables the quick assessment of a large population of particles. Microscopy may also be used to evaluate morphology and discover odd particles or agglomerates depending on the technique and substance.

What matters is the analytical procedure. The reported distribution may be influenced by sample preparation, dispersion circumstances, concentration, measurement settings, and presence of agglomerates. Hence, particle-size findings obtained in various labs should not be compared carelessly unless the analytical processes are sufficiently similar.

For pharmaceutical procurement this implies that a stated D50 value is more significant when it is supported by a well-defined test technique and a consistent sampling strategy.

Batch-to-batch comparison is where PSD becomes commercially important

In development work, a single test of particle size may provide a good deal of information. More disturbing is the repeatability in commercial supplies.

Assume that a batch has a D50 identical to the previous batch but a D90 very different. The median has not changed, but the top end of the distribution has moved. Depending on formulation, such a difference may be important to powder flow, blending, solubility, or other processing properties.

That is why purchasers should look at past batch data when available instead of relying on one certificate of analysis. Consistent PSD across numerous manufacturing lots gives more robust evidence of process control than a single measurement.

What buyers should consider when sourcing Tadalafil Powder？

Look beyond the smallest advertised particle size

A supplier advertising a very small particle size may initially appear attractive, but the smallest possible particle size is rarely the only factor that determines suitability.

A buyer should first establish what the intended formulation requires. A conventional tablet, an oral suspension, a solid dispersion, and a more advanced delivery system may have very different physical requirements for Tadalafil Powder. The target should therefore be based on formulation development data rather than a generic marketing number.

The buyer should also consider whether the supplier can discuss PSD using meaningful parameters such as D10, D50, and D90, whether the test method is defined, and whether batch-to-batch results are monitored.

Ask how the supplier controls physical consistency

A strong API supplier should be able to explain how particle characteristics are controlled during manufacturing without relying on vague claims about “advanced technology.”

Useful quality documentation may include a certificate of analysis, specification sheet, particle-size testing information, and relevant quality-system documentation. Depending on the project, buyers may also need information on assay, related substances, residual solvents, water content, polymorphic form, and other attributes that can affect formulation development.

For Hongda Phytochemistry and Shaanxi Hongda Phytochemistry Co., Ltd., this broader quality perspective is more useful than presenting particle size as a standalone selling point. A pharmaceutical buyer ultimately needs confidence that the supplied API can be evaluated against defined specifications and reproduced consistently from batch to batch.

Why particle-size control matters during scale-up？

Laboratory performance does not automatically transfer to production

A particle-size distribution that performs well in a laboratory formulation may behave differently after the process is scaled up. Changes in blending equipment, powder handling, feed rate, compression conditions, or dispersion energy can expose physical differences that were less obvious during development.

This is one reason formulation teams often establish critical material attributes during development. Particle size may become important when it has a demonstrated relationship with a critical quality attribute such as dissolution, content uniformity, or manufacturability.

The relationship should be demonstrated rather than assumed. If changing particle size produces a measurable and reproducible change in dissolution, then PSD may deserve tighter control. If the formulation is relatively insensitive within a certain range, an unnecessarily narrow specification could increase manufacturing cost without providing a meaningful quality benefit.

Consistency can be more valuable than extreme performance

For commercial pharmaceutical manufacturing, predictable material behavior is often more valuable than achieving an extreme physical characteristic.

A moderately fine powder with a stable distribution may be easier to process than an ultra-fine powder that varies significantly between batches. Similarly, a controlled PSD may simplify formulation development because engineers can work with a material whose behavior is reasonably consistent.

This is particularly relevant for long-term API sourcing. Once a formulation has been developed and validated around a defined raw-material profile, unexpected changes in particle characteristics can trigger additional investigation and potentially create qualification or scale-up work.

Conclusion

Particle size can have a meaningful effect on the performance of Tadalafil Powder, particularly through its influence on surface area, wetting, powder handling, and dissolution rate. Because tadalafil has low aqueous solubility and is commonly treated as a BCS Class II drug substance in pharmaceutical development, dissolution-related characteristics deserve careful consideration.

At the same time, particle size should not be treated as a simple rule in which smaller always means better. Particle-size distribution, morphology, crystal properties, agglomeration, formulation composition, and analytical method can all influence the final result. Pharmaceutical research on poorly soluble compounds supports particle-size reduction as one useful formulation strategy, but it is only one part of a broader development process.

For buyers, the most practical approach is to evaluate Tadalafil Powder through a complete quality profile. Consistent D10, D50, and D90 data, an appropriate particle-size testing method, reliable batch-to-batch control, and supporting API quality documentation can provide a much stronger basis for supplier qualification than a single advertised particle-size figure.

Hongda Phytochemistry and Shaanxi Hongda Phytochemistry Co., Ltd. can position their Tadalafil Powder supply around this quality-oriented approach, with particle characteristics considered as part of overall API consistency rather than as an isolated marketing claim. For pharmaceutical manufacturers, that distinction matters: the objective is not simply to obtain smaller particles but to obtain a reproducible material whose physical characteristics are compatible with the intended formulation and manufacturing process.

Contact duke@hongdaherb.com today to discuss how our particle-engineered tadalafil solutions can enhance your pharmaceutical formulations and gain a competitive advantage in global markets.

References

1. Varshosaz J, Ahmadi S, Ahmadi S. Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles. Research in Pharmaceutical Sciences, 2017, 12(3):222-232.

2. Mahmoud DB, Shukr MH, Bendas ER. Evaluation of Tadalafil Nanosuspensions and Their PEG Solid Dispersion Matrices for Enhancing Its Dissolution Properties. AAPS PharmSciTech, 2014, 15(2):364-374.

3. Eskandari M, Haeri A, Dadashzadeh S. Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment. International Journal of Pharmaceutics, 2019, 563:157-168.

4. Mohammadi G, Barzegar-Jalali M, Valizadeh H, Nazemiyeh H, Barzegar-Jalali A, Siahi Shadbad MR, Adibkia K. Enhanced Dissolution Rate of Tadalafil Nanoparticles Prepared by the Sonoprecipitation Technique. Iranian Journal of Pharmaceutical Research, 2017, 16(Suppl):44-54.

5. Lee DH, Park JS, Choi HG, Jin SG. Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats. Journal of Drug Delivery Science and Technology, 2021, 63:102418.